HEART DISEASE KILLS MORE PEOPLE EACH YEAR THAN COVID
Even in the era of COVID-19, and partly because of the side effects of COVID-19, Heart Disease is still the leading cause of death in the U.S., with more than 650,000 dying each year (White House, Briefing Room, 2022). It is a huge task on your part to combat such a heavy and widespread problem.
And this isn’t a problem for just the older generation anymore, nor is it specific only to males. This includes males and females. Obesity, alcohol, smoking, and high blood pressure affect patients of all ages and genders. (awarenessday.com, “American Heart Month”). Although heart disease is sometimes thought of as a man’s disease, it is the leading cause of death for women in the United States (CDC, “Women and Heart Disease”).
That’s why we are sharing GIBLIB content and resources that cover updates and innovations in cardiology to your practice through our Mayo Clinic course – “Cardiology Update: The Heart of the Matter”.
GIBLIB COURSE FOR HEART DISEASE – CARDIOLOGY UPDATE: THE HEART OF THE MATTER
This course features a wide spectrum of the latest updates in congestive heart failure, pulmonary hypertension, coronary artery disease, cardiac arrhythmias, congenital heart disease, anticoagulation, preventive cardiology, cardio-genomics, sports cardiology, and valvular heart disease, among others.
For example, the most common heart disease is coronary artery disease (CAD), which leads to heart attacks (speakersfornurses.com, “American Heart Month”). In just one of the videos in this course, “Updates in Hypertension Management: For Primary and Secondary Prevention of CAD,” Amy W. Pollak, MD reviews the management of hypertension based on ace CVD risk stratification, to understand what's new in hypertension management, and then to explore the treatment of resistant and refractory hypertension, which one of the areas that's challenging for all of us.
She outlines the stages of hypertension and when to treat based on a CVD risk, then going to diet and lifestyle and then end with resistance and refractory hypertension. You can learn this and more in our course “Cardiology Update: The Heart of the Matter”.
Here are 6 out of the 32 Video Lectures in this course on Heart Disease You can Watch on GIBLIB! Click on one or all the links to start watching.
Thomas G. Allison, PhD, MPH, uses cases to illustrate how to evaluate and treat athletes with dyspnea.
Learning Objectives: Review cases of patients with athletic dyspnea and Allison, PhD, MPH’s recommendations; Test your knowledge of athletic dyspnea; Review the many potential causes of dyspnea on exercison (DOE) and special concerns in athletes; Explore effective testing methods for dyspnea work-up; Identify why CPET is a critical element in your evaluation.
Michael J. Bryan, MD, discusses the current pre-participation examination guidelines for high school and college athletes.
Learning Objectives: Explore the current state of the pre-participation examination (PPE); Identify the most common causes of sudden cardiac death amongst young athletes; Identify recommended screening interventions by age group (high school, college); Review evidence behind current recommendations for pre-participation evaluation (PPE).
John P. Sweeney, MD, discusses the use of TAVR in the United States and improvements in technology.
Learning Objectives: Cover clinic trials of TAVR and how TAVR has lead to development for inoperable patients; Explain the intermediate and high risks involved in TAVR; Review the durability issues associated with valves and bioprosthetic value deterioration failure, and how TAVR helps; Cover necessary pacemaker implementation.
Julie L. Rosenthal, MD, discusses the presentation, testing, and diagnosis of Cardiac Amyloidosis.
Learning Objectives: Recall diagnostic criteria for cardiac amyloidosis; Recognize appropriate use & limitations of 99m technetium pyrophosphate scintigraphy; Review current & emerging amyloid targeted interventions.
Regis I. Fernandes, MD, discusses the use of a calcium artery score to assess the risk for atherosclerotic cardiovascular disease.
Learning Objectives: Review CAC uniqueness as an ASCVD risk protector; Identify pathobiology of coronary artery calcification; Cover trials that illustrate CAC’s effectiveness for improving ASCVD risk protection than other nontraditional markers; Explore guidelines for the use of CAC scoring and the effect age, gender, and race on the results.
Shimoli V. Shah, MD, uses cases to illustrate cardiotoxic effects with newer cancer treatments, identify clinical tools to detect cardiotoxicity and treatment options.
Learning Objectives: Describe short-term and delayed cardiotoxic effects associated with newer cancer treatments; Identify currently available clinical tools that can be used to detect cardiotoxicity; Review currently available treatment options to address cardiovascular toxicity; Recognize when a CAC examination is not recommended for patients.
Subscribe today to watch all 32 videos in the full course and earn CME credits with a premium subscription.
Also check out this toolkit from the CDC, designed for health care professionals and clinicians to help support their patients’ hypertension control. The CDC will help your clinical team implement protocols, use data to improve health outcomes, and inspire you with other practices’ success stories.
The CDC toolkit for heart disease reviews how to:
- Identify patients with hypertension.
- Incorporate lessons learned from success stories.
- Share messages and graphics with your care teams to help patients control their hypertension.
- Use these tools in tandem with the actions recommended in The Surgeon General’s Call to Action to Control Hypertension.